Northland Capital Partners upgraded shares of Cyberonics (NASDAQ: CYBX) from an under perform rating to a market perform rating in a report issued on Thursday, Analyst Ratings Network.com reports. They currently have $44.00 target price on the stock, up from their previous target price of $40.00.
Other equities research analysts have also recently issued reports about the stock. Analysts at Lazard Capital Markets cut their price target on shares of Cyberonics from $57.00 to $52.00 in a research note to investors on Wednesday, May 29th. They now have a buy rating on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of Cyberonics from $59.00 to $49.00 in a research note to investors on Wednesday, May 29th. They now have a buy rating on the stock. Finally, analysts at Jefferies Group reiterated a buy rating on shares of Cyberonics in a research note to investors on Wednesday, May 29th. They now have a $49.00 price target on the stock, down previously from $58.00.
Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $53.80.
Shares of Cyberonics (NASDAQ: CYBX) opened at 52.16 on Thursday. Cyberonics has a 52 week low of $40.06 and a 52 week high of $56.73. The stock’s 50-day moving average is currently $46.45. The company has a market cap of $1.438 billion and a P/E ratio of 31.42.
Cyberonics, Inc. (NASDAQ: CYBX) is a neuromodulation company engaged in the design, development, sales and marketing of implantable medical devices that provide a therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression.